Levonorgestrel 1.5 MG Oral Tablet [Option 2] — RxCUI 1736014
RxNorm drug concept · Semantic branded drug
RxCUI 1736014
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1736014
Official nameLevonorgestrel 1.5 MG Oral Tablet [Option 2]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asOption 2 1.5 MG Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)627 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Levonorgestrel: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- They both contain levonorgestrel, but they work very differently. The IUS (like Mirena, Liletta, Kyleena, or Skyla) is a small device a provider places inside your uterus that slow...
- What's the difference between the IUS and the emergency contraceptive pill — are they the same thing?
- The sooner the better — you should take it within 72 hours (3 days) of unprotected sex. It becomes less effective the longer you wait, so don't delay. If you vomit within 2 hours o...
- How quickly do I need to take the emergency contraceptive tablet after sex?
🕸️ Concept Web — How Levonorgestrel 1.5 MG Oral Tablet [Option 2] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Levonorgestrel 1.5 MG Oral Tablet [Option 2]
RxCUI 1736014 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Levonorgestrel
6373IN
-
Levonorgestrel
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Option 2
1736009BN
-
Option 2
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Levonorgestrel Oral Tablet
372591SCDF -
Levonorgestrel Oral Product
1163477SCDG -
Levonorgestrel Pill
1163478SCDG -
Levonorgestrel Oral Tablet [Option 2]
1736011SBDF -
Option 2 Oral Product
1736012SBDG -
Option 2 Pill
1736013SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Levonorgestrel Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Levonorgestrel 1.5 MG Oral Tablet
483325SCD -
Levonorgestrel 1.5 MG
483324SCDC -
Levonorgestrel 1.5 MG [Option 2]
1736010SBDC
-
Levonorgestrel 1.5 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Levonorgestrel 1.5 MG Oral Tablet
SCD · 483325 -
Levonorgestrel 1.5 MG
SCDC · 483324 -
Levonorgestrel Oral Tablet
SCDF · 372591 -
Levonorgestrel Oral Product
SCDG · 1163477 -
Levonorgestrel Pill
SCDG · 1163478
Brand-Name Concepts
-
Levonorgestrel 1.5 MG [Option 2]
SBDC · 1736010 -
Levonorgestrel Oral Tablet [Option 2]
SBDF · 1736011 -
Option 2 Oral Product
SBDG · 1736012 -
Option 2 Pill
SBDG · 1736013 -
Option 2
BN · 1736009
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 1736014 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00113-2003-12 | 1 BLISTER PACK in 1 CARTON (0113-2003-12) / 1 TABLET in 1 B... | Option 2 | L. Perrigo Company | 2016-01-29 |
| 00113-8099-12 | 1 BLISTER PACK in 1 CARTON (0113-8099-12) / 1 TABLET in 1 B... | OPTION 2 | L. Perrigo Company | 2026-04-20 |
Observed labelers:
L. Perrigo Company (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$6.4035
Range $6.4035–$6.4035
· middle 50% $6.4035–$6.4035
· 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.